CRISPR/Cas9: From Genome Engineering to Cancer Drug Discovery.

Authors:
Ji Luo

Trends Cancer 2016 06;2(6):313-324

Laboratory of Cancer Biology and Genomics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20814, USA.

Advances in translational research are often driven by new technologies. The advent of microarrays, next-generation sequencing, proteomics and RNA interference (RNAi) have led to breakthroughs in our understanding of the mechanisms of cancer and the discovery of new cancer drug targets. The discovery of the bacterial clustered regularly interspaced palindromic repeat (CRISPR) system and its subsequent adaptation as a tool for mammalian genome engineering has opened up new avenues for functional genomics studies. This review will focus on the utility of CRISPR in the context of cancer drug target discovery.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.trecan.2016.05.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461962PMC
June 2016
5 Reads

Publication Analysis

Top Keywords

cancer drug
12
genome engineering
8
interspaced palindromic
4
regularly interspaced
4
palindromic repeat
4
crispr system
4
subsequent adaptation
4
system subsequent
4
clustered regularly
4
repeat crispr
4
targets discovery
4
mechanisms cancer
4
understanding mechanisms
4
breakthroughs understanding
4
cancer discovery
4
discovery cancer
4
adaptation tool
4
drug targets
4
bacterial clustered
4
mammalian genome
4

Similar Publications